Biologics with specific cytokines, including Tnf-α, IL-17, or IL-23, can provide better efficacy and safety than traditional treatment strategies and have been approved by the FDA for treating moderate to severe psoriasis [17]. This evidence concerns the gene IL17A and psoriasis.